ArticleBMC pharmacology & toxicology2026
Lycopene attenuates DEHP-induced oxidative stress, mitochondrial dysfunction, and apoptosis in human granulosa cells via SIRT1-dependent mechanisms.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Di(2-ethylhexyl) phthalate (DEHP) is a widely used plasticizer and endocrine disruptor that can impair ovarian function by provoking oxidative stress, mitochondrial injury, and apoptosis in granulosa cells. Lycopene is a diet-derived carotenoid with antioxidant and mitochondria-protective activities. This study investigated whether lycopene protects human granulosa-like KGN and COV434 cells against DEHP-induced damage and whether SIRT1 mediates these effects. Cells were exposed to DEHP (50–800 µM) for 24–72 h to define concentration- and time-dependent cytotoxicity, followed by co-treatment with lycopene (1–3 µM). Cell viability was assessed using CCK-8, and apoptosis was evaluated by caspase-3/-7 activity. Intracellular reactive oxygen species (ROS) were quantified using DCFH-DA fluorescence. Mitochondrial function was assessed by JC-1 staining for mitochondrial membrane potential and by qPCR determination of mitochondrial DNA (mtDNA) copy number. Antioxidant defense and lipid peroxidation were evaluated by measuring superoxide dismutase (SOD) and catalase (CAT) activities and malondialdehyde (MDA) levels. SIRT1 expression was examined at the transcript and protein levels, and siRNA-mediated SIRT1 knockdown was used to test mechanistic dependence. DEHP significantly reduced cell viability and increased caspase-3/-7 activity in both cell lines, accompanied by ROS accumulation, loss of mitochondrial membrane potential, reduced mtDNA copy number, decreased SOD/CAT activities, and elevated MDA. Lycopene markedly mitigated these effects, restoring redox balance, antioxidant capacity, and mitochondrial integrity while suppressing apoptotic signaling. DEHP downregulated SIRT1, whereas lycopene restored SIRT1 expression, and SIRT1 silencing partially weakened lycopene-mediated cytoprotection. Collectively, these findings identify a SIRT1-dependent protective action of lycopene against DEHP-induced granulosa cell oxidative and mitochondrial injury, supporting lycopene as a potential strategy to mitigate phthalate-associated ovarian toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.